SPL5AC / SpliSense - LARVOL DELTA

SPL5AC, MUC5AC lowering ASO for CF and other muco-obstructive diseases (NACFC 2025) - "Restoring proper mucus viscoelasticity and clearance in the lungs of patients with muco-obstructive diseases like CF, remains a major goal. Our results demonstrate that SPL5AC ASO has a potential therapeutic benefit for CF and other muco-obstructive patients with the objective to advance to first in Human in 2026."

Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Inflammation • Respiratory Diseases • IL13 • MUC5AC • MUC5B

SPL5AC, MUC5AC Lowering ASO for cystic fibrosis and other muco-obstructive diseases (ECFS 2025) - "Restoring proper mucus viscoelasticity and clearance in the lungs of patients with muco-obstructive diseases like CF, remains a major goal. Our results demonstrate that SPL5AC ASO has a potential therapeutic benefit for CF and other muco-obstructive patients with the objective to advance to first in Human in 2025."

Asthma • Chronic Obstructive Pulmonary Disease • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Inflammation • Respiratory Diseases • IL13 • MUC5AC • MUC5B

SPL5AC an antisense oligonucleotide drug reducing MUC5AC as a therapeutic approach for CF and other muco-obstructive diseases (NACFC 2024) - "Restoring proper mucus viscoelasticity and clearance in the lungs of people with muco-obstructive diseases such as CF remains an important goal. Our results demonstrate that the SPL5AC ASO has a potential therapeutic benefit for people with CF and other muco-obstructive diseases, with the objective to advance to first in human in 2024."

Asthma • Bronchiectasis • Chronic Obstructive Pulmonary Disease • Genetic Disorders • Immunology • Infectious Disease • Inflammation • Non‐Cystic Fibrosis Bronchiectasis • Pulmonary Disease • Respiratory Diseases • MUC5AC • MUC5B

ASOs reducing MUC5AC or MUC5B as a therapeutic approach for CF and other muco-obstructive diseases (ECFS 2024) - "our results demonstrate that SPL5AC and SPL5B ASOs have a potential therapeutic benefit for CF and other muco-obstructive patients with the objective to advance to first in Human in 2024."

Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • MUC5AC • MUC5B

Reducing MUC5AC or MUC5B expression using antisense oligonucleotides as a therapeutic approach for cystic fibrosis and other muco-obstructive diseases (NACFC 2023) - "SPL5AC and SPL5B ASOs have potential therapeutic benefit in CF and other muco-obstructive diseases, with the objective of advancing to first-in-human trials in 2024."

Asthma • Chronic Obstructive Pulmonary Disease • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • MUC5AC • MUC5B